Roche buys US biotech firm InterMune for 拢5bn
- Published
Swiss pharmaceutical giant Roche has said it will buy maker of lung disease therapies InterMune for $8.3bn (拢5bn).
Intermune, which is based in Brisbane, California, makes a medicine for idiopathic pulmonary fibrosis, a deadly disease which scars the lungs.
The deal is the latest in a string of mergers in the drugs sector.
It is also the largest by Roche since 2009 when it bought the remainder of Genentech for about $47bn.
Pharmaceutical mergers
Roche will pay $78 per share in InterMune, which is a premium of 38% on top of the value of the shares at the end of last week.
Recent deals in the drug sector include US drug firm AbbVie's purchase of the UK pharmaceutical company Shire for 拢32bn.
UK High Street chemist Alliance Boots was bought up by US pharmacy giant Walgreens in an agreement earlier this month.
In May, pharmaceutical company Pfizer dropped a bid for UK company AstraZeneca.
- Published18 July 2014
- Published6 August 2014
- Published26 May 2014
